The cancer therapy developer and Jackson Laboratory spinout floated at the upper end of its range and now has a $600m market cap.

Novo and Celgene will retain shares in the cancer therapy developer, which floated at the upper end of its range and which now has a $600m market cap.

The antibody-based drug developer, which counts WuXi AppTec, Fosun, Sinopharm and Humanwell as investors, has floated in a $126m offering.

Behavioural health platform developer Brightline captured $72m in a round led by GV, while Gopuff is set to buy Siemens and ST-backed mobility software producer RideOS.

The GlaxoSmithKline and Celgene-backed immunotherapy developer has floated in the middle of its range on the Nasdaq Global Market.

The Mitsui-backed money transfer service formerly known as TransferWise was valued at $5bn in a secondary share sale almost a year ago.

University of Ulm spinout WITec has agreed to a $50m acquisition by Oxford Instruments, itself the first-ever spinout of University of Oxford.

11Street and CJ Group contributed to a $71.8m round for on-demand logistics provider Barogo while Eli Lilly helped provide $66m for macrocycle drug developer Circle Pharma.

The payment card technology provider, which counts Visa, CommerzBank, CreditEase and Mastercard as investors, has added about $190m to close its IPO.

Broad Institute and UPenn-linked cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.